Drug Trial Radar · NCT03264664
Study of E7386 in Participants With Selected Advanced Neoplasms
Last checked: Nov 19, 2026Latest source record: Jun 8, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
60
Planned (sponsor's estimate)
Start
Jul 27, 2017
Primary completion
Mar 31, 2027
Study completion Mar 31, 2027
Sponsor
- Lead sponsor
- Eisai Inc.Eisai
- Sponsor type
- Industry
- First posted
- Aug 29, 2017
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This study will be conducted to assess the safety/tolerability profile of E7386 as a single agent administered orally in participants with selected advanced or recurrent neoplasms and to determine the maximum tolerated dose (MTD) and/or recommended Phase 2 dose (RP2D) of E7386.
Conditions
- Advanced Neoplasms
Interventions
E7386Drug
Oral immediate release tablets.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Number of Participants With Dose-limiting Toxicities (DLTs)Time frame: Cycle 1 (28 days)
- Recommended Phase 2 Dose (RP2D)Time frame: Cycle 1 (28 days)
- Number of Participants with Treatment Emergent Adverse Events (TEAEs)Time frame: From the date of first dose of study drug up to 28 days after administration of study drug (up to approximately 6 years and 10 months)
Locations
10 sites in 2 countries. Site status is shown where the registry gives one.
Mayo Clinic Comprehensive Caner
Phoenix, Arizona
USC Norris Comprehensive Cancer Center
Los Angeles, California
California Liver Research Institute
Pasadena, California
Mayo Clinic Comprehensive Cancer
Jacksonville, Florida
Mayo Clinic Comprehensive Caner
Rochester, Minnesota
UT Southwestern Medical Center
Dallas, Texas
Imperial College Healthcare NHS Trust
London, United Kingdom
The Beatson West of Scotland Cancer Centre
Glasgow, Lanarkshire, United Kingdom
The Christie NHS Foundation Trust
Manchester, Lancashire, United Kingdom
Royal Marsden Hospital NHS Foundation Trust
Sutton, Surrey, United Kingdom
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.